Home › Cervical Cancer › Arizona › Phoenix
Cervical Cancer clinical trials in Phoenix, AZ
3 studies for Cervical Cancer are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
RecruitingObservational study
- Mayo Clinic, Phoenix
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
- HonorHealth Cancer Care - Biltmore - AZCCC Imaging, Phoenix
- HonorHealth Cancer Care - Biltmore - HonorHealth Research Pharmacy, Phoenix
- HonorHealth Research Institute (Arizona Center for Cancer Care) - HonorHealth Cancer Care -Biltmore, Phoenix
- and 2 more
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecruitingObservational study
- Mayo Clinic in Arizona, Phoenix
About Cervical Cancer
Cervical cancer starts in the cells of the cervix, which is the lower, narrow end of the uterus. Long-lasting HPV infection causes almost all cervical cancers.
More about Cervical Cancer on MedlinePlus
Cervical Cancer trials in other cities
- Houston, TX34 studies
- Nashville, TN19 studies
- New York City, NY19 studies
- Boston, MA18 studies
- Los Angeles, CA16 studies
- Arlington, VA16 studies
- San Antonio, TX14 studies
- St. Louis, MO13 studies
- Dallas, TX13 studies
- Orlando, FL12 studies
- Chicago, IL12 studies
- Columbus, OH11 studies
Other studies in Phoenix
- Breast Cancer25 studies
- Colorectal Cancer25 studies
- Obesity22 studies
- Non-Small Cell Lung Cancer20 studies
- Metastatic Cancer20 studies
- Heart Failure18 studies
- Prostate Cancer17 studies
- Cancer (all types)17 studies
- Multiple Myeloma16 studies
- Pancreatic Cancer16 studies
- Cardiovascular Disease16 studies
- Alzheimer's Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.